In adults, for the treatment of: – cryptococcal meningitis; – coccidioidosis; – invasive candidiasis; – mucosal candidiases including candidiasis of the oropharynx and oesophagus, candiduria, chronic candidiasis of the skin and mucosa; – chronic atrophic candidiasis (candidiasis caused by the use of dentures) if local therapy is ineffective. In adults, for the prevention of: – relapse of cryptococcal meningitis in patients with a high risk of its development; – relapse of candidiasis of the oropharynx and oesophagus in patients with HIV with a high risk of its development; – prevention of candidal infections in patients with prolonged neutropenia (e.g. in patients with blood malignancies receiving chemotherapy, or in patients with haematopoietic stem cell transplantation).